You Hit Your Goal Weight on a GLP-1 — Now What? Stay, Step Down, or Stop

You hit the number. The one you wrote on a sticky note months ago, the one that felt like a fantasy when the nausea was at its worst. The scale says it back to you on a regular Tuesday, and for about a day it feels like crossing a finish line.

Then a quieter question moves in and sits down. Is this it now, a shot every week for the rest of my life? Can I stay here on a smaller dose? What happens if I just... stop?

That's the part almost nobody warns you about. Losing the weight and keeping it off are two different projects, and the second one comes with its own set of choices. There are three roads out of goal weight, and the trials have a fair amount to say about where each one leads.

Reaching your goal opens a new decision

For most of the way up the dose ladder, the goal pulls you forward. The titration schedule does the steering. You go 0.25, then 0.5, then 1.0, climbing toward whatever your body tolerates. You're aiming at a target.

Hit it, and the road forks. Nobody hands you a map at the fork, which is why this stage catches so many people off guard. You spent months thinking about how to lose. Now the question flips to how to hold, and it turns out those need different answers.

Weight loss and weight maintenance are two different tasks. Your body has spent this whole time defending its old set point, turning down energy use and turning up hunger signals. Hitting goal doesn't switch that off. So the question in front of you stops being "did it work" and becomes "what now, given that my body still wants the weight back."

Three roads: stay, step down, or stop

There are exactly three things you can do with the medication once you reach a weight you're happy with.

Stay on the maintenance dose that got you to goal, kept exactly as is. Step down to a lower maintenance dose. Or stop: wind it down and try to hold the loss without the drug.

Each one is a real, legitimate option for a real person, and the right one depends on your situation more than on any fixed rule. Cost matters. So does how the side effects feel month after month. So does what your body does when the dose changes. Here's a quick map before we get into what the data shows for each.

That's the whole decision in one frame. The rest of this is the evidence under each row, because "what feels right" gets a lot clearer once you know what tends to happen.

What stopping actually does

Start with the road people are most tempted by, because it's free and it feels like graduation. You did the hard part; surely now you can coast on willpower and new habits.

The cleanest look at this comes from a trial called STEP 4. Everyone in it took semaglutide for the first 20 weeks. That was a run-in, to get them up to dose and losing. Then the group was split. One group kept taking the drug. The other was switched to placebo, a dummy injection, without knowing it.

Over the next stretch, the two groups drifted apart fast. The people who stayed on semaglutide kept going, landing at a mean weight change of -7.9%. The people switched to placebo went the other way, to a mean change of +6.9%. Same starting point, opposite directions.

Read that gap carefully, because it's easy to misread. The full difference between the two groups is two things added together. Part of it is the placebo group regaining most of what they'd lost. The rest is the continued group still losing a little more. So stopping didn't freeze progress where it was. It reversed it, while staying on kept it moving.

Stopping the medication didn't lock in the loss. The weight started coming back, while the people who stayed on kept losing a bit more.

This is the finding that changes how you read the whole thing. The drug was holding a result the body kept pushing against. Take it away and the body does what it was always trying to do.

Staying on, two years in: does the loss hold?

The obvious next question: fine, it holds for a while, but does it keep holding? A few months is one thing. Years is another.

That's the question STEP 5 was built to answer, and it ran a full two years. Same design idea, semaglutide versus placebo, but stretched out to 104 weeks so you could see whether the effect fades.

It didn't fade. From baseline out to week 104, the continued-semaglutide group sat at a mean change of -15.2%. The placebo group? -2.6%. Two full years in, the gap was still wide open.

Put STEP 4 and STEP 5 side by side and the shape of it lands. Stop, and the curve turns back up within months. Stay, and the loss is still there two years later. The medication isn't doing a one-time job and clocking out. It holds the line for as long as it's on board.

One caveat worth saying plainly: -15.2% is a trial average. Individual responses vary, and averages aren't promises. "Staying on works" is a strong pattern. It's not a personal guarantee, and your own curve is yours.

The label already includes a lower dose

Here's the piece that surprises people: stepping down isn't some gray-area hack you talk your doctor into. The US FDA label already spells out a lower maintenance option.

For Wegovy, the semaglutide brand approved for weight management, the label lists a maintenance dose of 2.4 mg once weekly as the recommended option, plus 1.7 mg once weekly as a defined alternative. So a lower-than-peak maintenance dose isn't off-script. It's printed right there in the prescribing information.

The label adds the part that matters most, though. It tells clinicians to weigh treatment response and tolerability when choosing the maintenance dose. In plain terms, which maintenance dose you land on is a clinical decision, made with the person who prescribes for you. It's the kind of call to make with your prescriber, not a dial you turn on your own to save money or dodge a rough week.

Lowering to a maintenance dose is a defined path in the label, and the label puts that choice in your clinician's hands.

A quick but real note on naming, because it trips people up across borders. That 2.4 mg / 1.7 mg maintenance structure is the US FDA label. Approvals, brand names, and exact dosing can differ wherever you are, so the version your own regulator and prescriber work from is the one that counts.

The trial built to ask this exact question head-on

So far the evidence answers two of the three roads cleanly. Stopping leads to regain, staying holds the loss. The middle road, the step-down, is where the honest answer has been "we're still finding out."

That's changing, because researchers built a trial to compare all three paths directly. It's called SURMOUNT-MAINTAIN, and its whole design is the stay/step-down/stop question put under one roof.

Here's how it's set up. People who'd already reached a maintenance phase on tirzepatide were split into three groups, in a 3:3:2 ratio. One group continues tirzepatide at the maximum tolerated dose. One steps down to 5 mg. One switches to placebo, which is the stop arm. A total of 441 people were enrolled. Continue, step down, or stop, measured against each other in the same study.

I want to be careful here, because this is the kind of thing it's tempting to oversell. As of its design publication, SURMOUNT-MAINTAIN was still running, expected to wrap by early 2026. The results aren't out. So I can't tell you the step-down arm held X% or that it beat anything. Nobody can yet, and any number you see claiming otherwise is made up.

What I can say is this: the question that's been answered only in pieces, what's the right long-term dose once you're at goal, finally has a trial designed to test it directly, three roads at once. That's the news. The data to fill it in is on the way.

Why this quietly reframes obesity as a chronic condition

Line the trials up and they tell one story. STEP 4: stop and you regain. STEP 5: stay and you hold for two years. SURMOUNT-MAINTAIN: a whole trial built around the idea that the dose question keeps going after the weight loss is done.

These all point at the same conclusion the researchers themselves draw. Obesity behaves like an ongoing condition you manage, the way you manage blood pressure or cholesterol. The result holds as long as the treatment does. It isn't something you finish and walk away from.

It can sound grim at first, but it's really the same logic we already accept for plenty of conditions. Nobody calls it a failure when someone keeps taking their blood-pressure medication after their numbers come down. The medication is the reason the numbers stay down. This is the same shape.

What it does rule out is the fantasy version, where a GLP-1 gives you a temporary boost to a new, self-sustaining you. The trials are fairly direct. For most people, the loss is held by continued treatment, in whatever form you and your clinician land on.

Regaining weight after stopping is physiology, not a personal failure

This part needs saying on its own, because the shame around it does real damage.

When people stop a GLP-1 and the weight comes back, the story they tell themselves is usually the cruelest one: I had no willpower, I let it slip, I blew it. The STEP 4 data tells a different story. The regain showed up across the group that stopped. Those people weren't weaker; the biology that defends your old weight simply switched back on when the drug came off.

That distinction is kinder, and it's also more accurate, and it changes what you do next. If regain is a character flaw, the fix is to white-knuckle harder. If regain is physiology, the fix is a conversation about treatment: maybe staying on, maybe a maintenance dose, maybe a different plan entirely. The first framing sends you spiraling. The second sends you back to your doctor with a clear question.

Regain after stopping isn't proof you failed. It's your body doing what it was built to do, which is why the right response is a treatment plan worked out with your clinician.

And the flip side of that coin: please don't try to engineer your own version. Quietly halving your dose to stretch a prescription, or stopping cold and hoping, is the kind of move that turns a manageable decision into a regain you didn't plan for. The dose changes that work are the ones made on purpose, with the person who knows your full picture.

Picking a road, with your clinician

So you're at goal, looking at three roads. How do you pick?

Honestly, the first move is to stop thinking of it as a solo decision. The whole reason the label says "consider treatment response and tolerability" is that the right dose depends on things only your clinician can weigh with you: how you responded, how the side effects sit, what your other health conditions are doing.

A few things worth bringing to that visit, in your own words:

• How has the weight held at this dose, and what tends to happen if we lower it?
• Given the STEP 4 and STEP 5 data, what does staying on look like for someone like me?
• If cost or side effects are the issue, is a maintenance dose a reasonable middle road?
• What's our plan if the weight starts creeping back?

None of that is asking permission to be done. You're asking for a maintenance strategy, which is its own thing, separate from the strategy that got you here. The drug is one tool inside a longer plan that includes how you eat, how you move, and how you sleep. You manage it the way you'd manage any long-running condition, and the management has options.

The data we do have is consistent on the broad strokes: stopping tends to reverse the loss, staying on tends to hold it, and a lower maintenance dose is a defined path your label already recognizes. The piece still being filled in, how the step-down stacks up directly, is exactly what SURMOUNT-MAINTAIN was built to measure, with results still ahead. Everything here comes from published clinical trials and regulatory labels, and what your own maintenance plan should be is a conversation for you and your prescriber, who knows your history.

You crossed the finish line you set. It turned out to be a starting line for a different race, a slower and steadier one, run with a clinician instead of a countdown clock. And now there's a trial built to fill in the last stretch: the head-to-head step-down question STEP 4 and STEP 5 couldn't answer.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app